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Pyruvate metabolisma b s t r a c t
Purpose: To estimate the rate constant for pyruvate to lactate conversion in tumours in response to a
hypoxic challenge, using hyperpolarised 13C1-pyruvate and magnetic resonance spectroscopy.
Methods and materials: Hypoxic inspired gas was used to manipulate rat P22 ﬁbrosarcoma oxygen tension
(pO2), conﬁrmed by luminescence decay of oxygen-sensitive probes. Hyperpolarised 13C1-pyruvate was
injected into the femoral vein of anaesthetised rats and slice-localised 13C magnetic resonance (MR)
spectra acquired. Spectral integral versus time curves for pyruvate and lactate were ﬁtted to a precur-
sor-product model to estimate the rate constant for tumour conversion of pyruvate to lactate (kpl).
Mean arterial blood pressure (MABP) and oxygen tension (ArtpO2) were monitored. Pyruvate and lactate
concentrations were measured in freeze-clamped tumours.
Results: MABP, ArtpO2 and tumour pO2 decreased signiﬁcantly during hypoxia. kpl increased signiﬁcantly
(p < 0.01) from 0.029 ± 0.002 s1 to 0.049 ± 0.006 s1 (mean ± SEM) when animals breathing air were
switched to hypoxic conditions, whereas pyruvate and lactate concentrations were minimally affected
by hypoxia. Both ArtpO2 and MABP inﬂuenced the estimate of kpl, with a strong negative correlation
between kpl and the product of ArtpO2 and MABP under hypoxia.
Conclusion: The rate constant for pyruvate to lactate conversion, kpl, responds signiﬁcantly to a rapid
reduction in tumour oxygenation.
 2015 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 116 (2015) 392–399
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Tumour hypoxia limits efﬁcacy of radiotherapy and some
chemotherapy drugs, as well as stimulating tumour progression
[1]. Treatment, in turn, can modify tumour oxygenation, including
vascular-targeted approaches speciﬁcally designed to inducesufﬁcient hypoxia to promote cancer cell death. Several imaging
methods have been tested clinically for monitoring tumour
hypoxia, such as the use of radio-labelled nitroimadazoles and
other redox-sensitive compounds for positron emission tomogra-
phy [2,3] and electron paramagnetic resonance (EPR) imaging [4].
Magnetic resonance spectroscopy and/or imaging (MRS/MRSI/
MRI) methods include oxygen-enhanced MRI, 19F oximetry using
perﬂuorocarbons and 1H MRI-based blood oxygen-level dependent
(BOLD) imaging [3,5]. Pre-clinical developments have been
reviewed by Mason et al. [6]. Dissolution dynamic nuclear polar-
isation (dDNP) of metabolic substrates combined with MRS/MRSI
is established pre-clinically for monitoring in vivo metabolism [7]
and its ﬁrst clinical use has now been published [8]. This technique
potentially provides a complementary MRS/MRSI-based method
for monitoring induced changes in tumour metabolism that are
inﬂuenced by oxygenation status.
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many orders of magnitude, allowing real-time kinetics of metabo-
lism to be followed in tissue without the interfering background
signals experienced in 1H MRS. In the glycolytic pathway, hyperpo-
larised 13C1-pyruvate (PA) has been the most studied substrate for
cancer metabolism because of its high, rapid hyperpolarisation and
relatively long T1 relaxation time [9,10]. Lactate dehydrogenase
(LDH) catalyses pyruvate to lactate production, accompanied by
oxidation of nicotinamide-adenine dinucleotide (NADH) to NAD+.
Altered metabolism is a common feature of cancers and many
tumour cells metabolise glucose to lactate under aerobic as well
as anaerobic conditions, a phenomenon known as aerobic glycoly-
sis or the Warburg effect [11]. Nevertheless, available data suggest
that the majority of tumour energy (ATP) production is via oxida-
tive phosphorylation (OXPHOS) [12] and that there is a switch
away from OXPHOS towards increased glucose consumption and
lactate production under acute hypoxic conditions (an inverse of
the classic Pasteur effect) [13,14]. Therefore, dDNP with PA has
the potential for directly monitoring the effect of tumour oxygena-
tion on metabolism. The aim of the current study was to establish
how the rate constant for tumour conversion of pyruvate to lactate
responds to an acute hypoxic challenge in a rat tumour model.
Methods and materials
Animal treatment groups
All experiments were conducted in accordance with the United
Kingdom Animals (Scientiﬁc Procedures) Act 1986 and following
published guidelines [15]. Rat P22 ﬁbrosarcoma fragments [16]
were implanted subcutaneously into the rear dorsum of male
BDIX rats. A cohort of tumour-bearing rats (n = 36) was used to
determine local tumour oxygen tensions (pO2) via probes
incorporating an oxygen-sensitive ﬂuorophore (OxyLite™). These
measurements were used to establish a suitable inspired gas mix-
ture for inducing tumour hypoxia in subsequent MRS experiments
(see Supplementary Materials). A second group of tumour-bearing
rats (n = 18) was used for MRS experiments, in which the rate con-
stant for conversion of intravenously administered PA into lactate
(kpl) in tumour tissue was estimated under normoxic and hypoxic
conditions. A third group of animals (n = 28) was used for ex vivo
measurement of pyruvate and lactate concentrations in tumour
tissue following the same gas challenges as used for MRS.Animal preparation for MRS
When tumours reached 18 ± 6 mmmean diameter (mean ± SD),
rats (300 ± 27 g; mean ± SD) were anaesthetised with isoﬂurane
and a femoral vein, a femoral artery and a tail vein cannulated.
Following surgery, rats were heparinised (1500 Units/kg i.v.) and
anaesthesia maintained for imaging by propofol (Rapinovet,
Intervet/Schering-Plough Animal Health, Milton Keynes, UK)
infused via the tail vein cannula at a rate of 40 mg/kg/h. Rectal
temperature was maintained at 37 C throughout surgery and
imaging, using a homoeothermic blanket system (Harvard
Apparatus, UK).Hyperpolarisation of 13C1-pyruvate and MR experiments
13C1-pyruvic acid (CIL, Andover, MA or Sigma Aldrich,
Gillingham, UK) was hyperpolarised (denoted PA) using a
HyperSense polariser as described previously [17], see
Supplementary Materials. After dissolution, PA had a ﬁnal concen-
tration of 150 mM. Rats were located at the centre of a 300 mm
bore, 7T magnet with 120 mm, 400 mT/m gradients and anAvance-II spectrometer (Bruker Biospin MRI GmbH, Ettlingen,
Germany). Arterial blood pressure was measured in the arterial
cannula via a pressure transducer (CWE Inc, Ardmore, PA) for
calculation of mean arterial blood pressure (MABP). Blood/tumour
pO2 was manipulated by supplying the inspired gas as normal air
or hypoxia (10% O2; 4% CO2: N2 balance) via either tracheal
intubation or face-mask at 1 L/min commencing 3 min prior to
PA infusion and maintained throughout the MRS experiment.
A 13C/1H 20 mm surface coil (Bruker), positioned 1–2 mm
above the tumour to minimise respiration artefact, was used for
MR acquisitions (see Fig. 1a and b and Supplementary Materials
for details). Brieﬂy, a structural (FLASH) image was obtained to
localise a slice for 13C-spectroscopy. 13C-MRS data acquisition
commenced with automated transfer of PA from the polariser
and infusion into the rat [18] via the femoral vein cannula (5 ml/
kg, corresponding to 0.5–0.7 mmol/kg, over 13 s). Generally, this
infusion rate had no effect on MABP. In the few cases where a
minor increase was observed, return to base-line occurred within
seconds. Each animal received two sequential PA infusions
60 min apart, both under air-breathing conditions in the
normoxia group and under air-breathing followed by hypoxic con-
ditions in the hypoxia group. Arterial blood was collected from the
arterial cannula, starting at 3 min post PA infusion, and analysed
for arterial blood oxygen tension (ArtpO2) using an ABL80 Flex
blood gas analyser (Radiometer Ltd, Crawley, UK).MR data processing and kinetic analysis
MR raw data were processed using custom MATLAB software
(MathsWorks Inc, Natick, MA). 13C1-pyruvate and 13C1-lactate
peaks were integrated from phase-adjusted spectra for each
acquired slice and time point (Fig. 1c). Signal integrals versus time
were ﬁtted to a previously validated precursor-product model
using the pyruvate signal time course as an input function for
lactate, from which the pyruvate to lactate conversion rate con-
stant, kpl, was estimated [17]. Since pyruvate and lactate have a
very similar molecular structure, it was assumed that changes in
oxygenation (or any other microenvironmental factor) affect T1
and T2 of 13C1 labelled pyruvate and lactate equally.Biochemical analysis
Concentrations of pyruvate and lactate in P22 ﬁbrosarcomas
were measured in a control, untreated group and groups where
the surgery, anaesthesia regime, timing of pyruvate infusions
(not hyperpolarised) and gas breathing conditions used in the
MR experiments were replicated. Rats were sacriﬁced 6 min after
the ﬁnal pyruvate infusion, where given. Tumours were rapidly
excised, freeze-clamped in liquid nitrogen and stored at 80 C
before biochemical analysis. Pyruvate and lactate concentrations
(performed at least in triplicate) were assayed spec-
trophotometrically, based on the levels of the co-factors, NAD+/
NADH. See Supplemental Material for details.Statistical analysis
Analysis was carried out using MATLAB software. Paired or
unpaired two-tailed Student’s t-tests, as appropriate, were used
for testing the signiﬁcance of differences between two groups.
ANOVA with Bonferroni post hoc testing was used for multiple
group comparisons. Linear regression analysis was used for
correlations between physiological parameters – ArtpO2 and
MABP. A p value of <0.05 was considered statistically signiﬁcant.
Fig. 1. (a) Conﬁguration of the animal setup in the magnet, showing location of surface coil, acetate phantom and cannulations, (b) axial FLASH image of the tumour. A
cartoon representation of the surface coil location and guide-lines for the tumour slice are also shown. (c) Example of a series of acquired 13C spectra (absolute mode) versus
time from the start of the infusion procedure (every third spectrum shown for clarity), from a rat under air-breathing conditions. Inset shows the 13C spectrum (absolute
mode) as a sum of the time-course spectra.
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Tumour oxygenation and physiological status
The basal local pO2 in P22 ﬁbrosarcomas was 18.0 ± 1.7 mmHg
(mean ± SEM), with no effect of tumour size in the range used
(Fig. S1). Preliminary experiments established that 10% O2 in
the inspired gas gave a rapid and reproducible average reduction
in tumour pO2 of 82% without compromising the welfare of the
animal. Tumour pO2 was signiﬁcantly reduced at 1 min from the
start of the hypoxic challenge (p < 0.05) and decreased further until
response reached a plateau after 3 min (4.2 ± 1.7 mmHg;
mean ± SEM; Fig. S2). 28% of the tumours had relatively hypoxic
readings (5 mmHg) prior to the hypoxic challenge (Fig. S1c).
ArtpO2 was signiﬁcantly reduced in the hypoxia group follow-
ing the 2nd PA infusion under hypoxia compared with that during
the previous air-breathing phase (p < 0.01; Fig. 2a). In thenormoxia group, infused twice under air-breathing conditions,
there was no signiﬁcant difference in ArtpO2 between the two
measurements (Fig. 2b). Conversely, MABP was signiﬁcantly
decreased at the time of the second PA infusions, for both air-
breathing and hypoxia-challenged animals (Fig. 2c and d).
Although this effect tended to be larger under hypoxia, the
decrease in MABP was not signiﬁcantly different between the
two animal groups and there was no direct correlation between
MABP and ArtpO2 (Fig. S3).Hyperpolarised pyruvate experiments
The tumour pyruvate to lactate conversion rate constant, kpl,
increased signiﬁcantly (p < 0.01) from 0.029 ± 0.002 s1 under air-
breathing conditions (1st PA infusion) to 0.049 ± 0.006 s1 under
hypoxic conditions (2nd PA infusion) (mean ± SEM; Fig. 3a).
There was also a tendency for kpl to increase between the two PA
Fig. 2. (a and b) ArtpO2 analysed after each PA infusion for the hypoxia group (n = 7 pairs) and normoxia group (n = 5 pairs). (c and d) MABP measured at the time of PA
injection for the hypoxia group (n = 10 pairs) and normoxia group (n = 8 pairs). Each symbol represents an individual animal. Box plots show the median line, with the box
edges representing the 25% and 75% quartiles. Whiskers extend to the furthermost value within 1.5 times the interquartile range from the 25% and 75% quartiles. Outliers are
plotted beyond the whiskers. ⁄p < 0.05; ⁄⁄p < 0.01.
Fig. 3. The rate constant for conversion of hyperpolarised 13C1-pyruvate to lactate, kpl, (s1), in P22 ﬁbrosarcomas for (a) hypoxia group (n = 10 pairs) and (b) normoxia group
(n = 8 pairs). Each symbol represents an individual animal. Box plot representations of the data are described in Fig. 2. ⁄⁄p < 0.01.
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nistered under air-breathing conditions, but this was not
statistically signiﬁcant (p = 0.21; Fig. 3b). Unexpectedly, kpl for
the 1st PA infusion was higher in the normoxia than in the hypoxia
group (p < 0.05; Fig. 3), despite nominally the same air-breathing
conditions.Relationship between kpl and physiological parameters
MABP and ArtpO2 were negatively correlated with kpl in the
hypoxia group (R2 = 0.40; p = 0.003 and R2 = 0.38; p = 0.011 respec-
tively) but not in the normoxia group (Fig. 4a and b). There was
also a signiﬁcant correlation between MABP and kpl, when the
mean data from each of the acquisition groups were combined(R2 = 0.93; p = 0.035; Fig. S4). The product of MABP and arterial
pO2 (MABP ⁄ ArtpO2) negatively correlated with kpl in the hypoxia
group during the hypoxic challenge, where MABP ⁄ ArtpO2 values
were below approximately 5000 mmHg2 (R2 = 0.61; p = 0.023)
(Fig. 4c). No correlation was found between MABP ⁄ ArtpO2 and
kpl in the normoxia group, consistent with the fact that
MABP ⁄ ArtpO2 was generally greater than 5000 mmHg2 (Fig. 4c).Biochemical analysis
Results from freeze-clamped tumour tissue (16 ± 4 s from ﬁrst
incision to freezing; mean ± SD) showed that administration of
exogenous pyruvate did not signiﬁcantly increase tumoural pyru-
vate concentrations, though the variance between individual
Fig. 4. kpl versus (a) MABP; (b) ArtpO2 and (c) MABP ⁄ ArtpO2 for the hypoxia and normoxia groups. Each symbol represents an individual animal. Data are ﬁtted to a linear
model. Filled diamonds represent the 1st PA infusion, open triangles represent the 2nd PA infusion. R2 values are shown, where the slopes of the ﬁtted lines are statistically
different from zero (p < 0.05).
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tration was signiﬁcantly higher in tumours during the hypoxic
challenge, compared to tumours in untreated rats (4.97 ± 0.67 ver-
sus 3.01 ± 0.19 lmol/g wet weight; mean ± SEM; p < 0.05; Fig. 5b).
There was also a tendency for lactate concentration and lac-
tate:pyruvate ratio (L/P) to be higher in tumours in the hypoxia
group, compared with the corresponding values in air-breathing
groups, where rats received pyruvate infusions (Fig. 5b and c).
However, these trends were not statistically signiﬁcant.
Discussion
We have detected a signiﬁcant hypoxia-induced increase in the
fractional rate constant (kpl) for conversion of pyruvate to lactate in
tumour tissue, using hyperpolarised pyruvate (PA) and 13C MRS.
We emphasise that kpl is a fractional rate constant (s1) and that
the rate of conversion of pyruvate to lactate (lmol s1 (g tissue)1)
is given by the product of kpl and the tissue pyruvate concentration
(lmol (g tissue)1). No signiﬁcant changes in the concentration of
pyruvate were observed in any of the treatment groups after the
administration of exogenous pyruvate, suggesting rapid basal turn-
over of pyruvate. The increase in kpl observed under hypoxic con-
ditions therefore indicates an increase in the rate of conversion
of pyruvate to lactate.
Allosteric inhibition of phosphofructokinase by ATP and citrate
is the primary mechanism for the Pasteur effect. The inverse of thiseffect under hypoxia results in increased pyruvate production via
glycolysis and its subsequent reduction to lactate, thus regenerat-
ing the NAD+ needed for glycolysis to proceed. Many other mecha-
nisms, such as inactivation of the mitochondrial enzyme pyruvate
dehydrogenase by hypoxia-induced reactive oxygen species [19]
are also likely to impact on an increased lactate dehydrogenase
(LDH)-catalysed lactate production under hypoxia. The ability of
P22 tumours to respond to hypoxia by increasing the rate of con-
version of pyruvate to lactate is also consistent with a predominant
expression of LDH-5 (see Supplementary data, Fig. S5). All LDH
isoenzymes have the ability to transform pyruvate to lactate and
back [20] but the predominance of LDH-5 would favour the for-
ward reaction. Our results are consistent with other studies, where
tumour cell metabolism during hypoxia was investigated using
MR-based methodology [14,21]. However, whilst long exposure
to hypoxia can result in gene expression changes and up-reg-
ulation of proteins, the much shorter timescale of our hypoxic
challenge can only be explained by a direct effect of hypoxia on
pyruvate metabolism.Relationship between kpl and tumour lactate and pyruvate
concentrations
Despite the increase in kpl observed under hypoxia, biochemical
analysis of freeze-clamped tumours only showed a signiﬁcantly
higher concentration of tumour lactate in hypoxic animals
Fig. 5. (a) pyruvate, (b) lactate concentrations in P22 ﬁbrosarcomas determined by
enzymatic assay in tumour extracts and (c) L/P ratio. Columns from left to right: the
control group underwent no surgery, pyruvate infusions or gas challenges; rats
received a single pyruvate infusion under air-breathing conditions
(ArtpO2 = 87 ± 7 mmHg); rats received two sequential pyruvate infusions under
air breathing conditions (ArtpO2 = 82 ± 10 and 87 ± 6 mmHg); rats received two
pyruvate infusions, the ﬁrst under air-breathing conditions,
ArtpO2 = 87 ± 12 mmHg), the second breathing 10% O2, 4% CO2: balance N2
(ArtpO2 = 52 ± 11 mmHg). Data = mean ± SEM; n = 4–8 per group; ⁄p < 0.05.
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exogenous pyruvate (control untreated group, Fig. 5). Possible
explanations are that excess pyruvate increased the rate of the
LDH reaction towards lactate production or that the length of time
under anaesthesia for pyruvate infusion induced hypoxia, even in
the air-breathing animals. However, these factors would also apply
in the MR experiments, suggesting that changes in kpl are a more
sensitive index of induced hypoxia than changes in lactate concen-
tration or the L/P ratio, even though pyruvate and lactate undergo
rapid inter-conversion [22,23]. Consistent with our biochemical
data, previous studies have shown that lactate concentration in
tumours is dependent upon a complex interplay of factors, not just
hypoxia [24–28]. For instance, excess lactate produced under
hypoxia can be rapidly metabolised by well-perfused cancer cells,
as a fuel source [29,30]. Alternatively, high levels of lactate can be
rapidly exported into the blood supply for metabolism elsewhere,
although we have not observed this in our previous experiments
[17].
A signiﬁcant increase in tumour kpl alongside only borderline
increases in lactate concentration under hypoxia could also be
explained by 13C spin exchange [31]. Here, 13C-lactate, metabolised
from PA, enters the tumour lactate pool, where its concentration ismuch lower than the endogenous 12C-lactate concentration.
Therefore, there is a higher probability that 12C-lactate, rather than
13C-lactate, is subsequently metabolised or exported, retaining 13C
spins within the lactate pool. Temporarily higher lactate levels in
tumours, under hypoxic conditions, would increase the likelihood
of 13C label being retained within the large lactate pool, resulting
in high estimations of kpl. In order to fully deﬁne the ultimate fates
of pyruvate in tumours, simultaneous steady-state concentrations
of metabolites and quantitative ﬂuxes between different metabolic
steps would need to be measured, as recently described for cancer
cells in culture [32].Relationship between kpl and physiological parameters
The tendency for kpl to be higher for the second PA infusion in
the normoxia group was most likely related to the measured
decrease in MABP between the ﬁrst and second acquisition; an
expected effect of general anaesthesia (Fig. 2). Exogenously
administered pyruvate, at a higher concentration than in our
experiments, was also found to increase tumour hypoxia, albeit
at later times than assessed in our experiments [33]. Overall, the
data shown in Figs. 4 and Fig. S4 suggest that MABP does inﬂuence
kpl. This is to be expected since MABP reﬂects tumour perfusion
pressure and we previously showed that MABP correlates directly
with blood ﬂow in the P22 tumour [34]. Reduced tumour blood
ﬂow would, in turn, reduce oxygen delivery to the tumour, and
therefore local pO2. In the hypoxia group, this effect would be exa-
cerbated by the reduction in oxygen delivery caused by the
decrease in ArtpO2. Indeed, the product of MABP and ArtpO2 was
strongly inﬂuential on kpl in the hypoxia group, where ArtPO2 val-
ues dropped signiﬁcantly. Unsurprisingly, this was not the case in
the normoxia group, where ArtpO2 values were at physiological
levels. General anaesthesia could have affected our results in other
ways. For instance, propofol has been found to decrease mitochon-
drial function in certain cell/tissue types [35], although this would
have been the case in both our treatment groups.
We found no correlation between ArtpO2 and MABP at the time
of PA infusion (Fig. S3), although we did note a very rapid reduction
in MABP immediately on switching to the hypoxic gas mixture
(data not shown), consistent with compensatory vasodilation.
The lack of correlation at later times is probably a reﬂection of
the highly complex homoeostatic mechanisms controlling oxygen
delivery to critical tissues and systemic blood pressure.
There was considerable inter-tumour heterogeneity in both
tumour kpl (Fig. 3) and pO2 (Fig. S1) but whether there is a direct
relationship between these two parameters is currently unknown.
In any case, kpl for the 1st PA infusion in the hypoxia group was
lower than kpl for the equivalent acquisition in the normoxia group,
under the same nominal air-breathing conditions (Fig. 3). This
discrepancy is likely to relate to the higher MABP recorded for
the former group (Fig. 2), which suggests a higher blood ﬂow rate
and oxygen delivery, as noted above. The data shown in Fig. S6
show that the pyruvate signal, indicative to some extent of pyru-
vate delivery to the tumour, was generally highest for the 1st PA
infusion in the hypoxia group, supporting this theory. Since ani-
mals were randomly allocated to groups, we can only assume that
the difference in the MABPs between the two groups occurred by
chance. Our data highlight the importance of measuring systemic
parameters such as MABP and ArtpO2 to monitor the physiological
status of animals throughout the duration of in vivo dDNP
experiments.Limitations and further developments
One potential limitation of the dDNP technique is that it
requires infusion of supra-physiological levels of 13C-pyruvate
398 Acute metabolic response to hypoxia in rat tumours[33,36]. The size of the tumour pyruvate signal was quite variable
in our experiments (Fig. S6a), despite the solid-state hyperpolar-
isation levels being very similar (Fig. S6b). Other factors such as
tumour size, blood ﬂow rate and coil position would impact on
the size of signal obtained, whereas only blood ﬂow rate would
affect the actual concentration of pyruvate in tumour tissue.
There was a non-linear increase in the lactate signal with increased
pyruvate signal (Fig. S6a), which did not plateau. Although not
deﬁnitive, these data suggest that tumour tissue is not saturated
with pyruvate by the high dose of pyruvate administered. Partial
tissue saturation was observed by Janich and colleagues [37] in
the rat liver, kidney and heart with lower doses of pyruvate (0.2–
0.4 mmol/kg) than used in the current study. Lower blood ﬂow rate
and thus slower dose delivery to tumours may explain these differ-
ences. Testing the validity of the common assumption that tumour
microenvironmental factors such as oxygenation and pH affect 13C
T1s of pyruvate and lactate equally would be informative, as differ-
ences would affect the kpl values obtained. Furthermore, our cur-
rent procedure provides only a single estimate of kpl per tumour.
In order to probe the well-known heterogeneity of the tumour
microenvironment, an imaging based method such as spectral-spa-
tial EPI [38] to highlight spatial variations in oxygenation changes
would be a useful development of the current methodology.
Conclusion
We have shown that the rate constant for pyruvate to lactate
conversion, kpl, responds signiﬁcantly to a rapid reduction in
tumour oxygenation. A full quantitative analysis of pyruvate
kinetics, including the acquisition of arterial input functions, would
also enable pyruvate clearance from blood to tissue to be
estimated. This provides the opportunity to investigate tumour
vascular function, in addition to oxygenation-related metabolism
changes, from a single PA infusion. Further studies incorporating
simultaneous measurements of tumour pO2 and kpl are warranted
and necessary to determine whether there is any relationship
between absolute tumour pO2 and kpl.
Since tumours are highly dependent on pyruvate metabolism to
lactate for progression, measurement of hyperpolarised pyruvate
metabolism in tumours by 13C MRS is starting to be assessed as a
way to monitor treatment efﬁcacy. Our results emphasise the need
to take oxygenation changes into account when interpreting dDNP
data from such studies.
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